Immune response to an indigenously developed hepatitis-B (Shanvac-B) vaccine in a tribal community of India.

Hepatitis-B infection is highly endemic among the primitive tribes of Andaman and Nicobar Islands, India. A pilot project of hepatitis-B vaccination using indigenously developed (Shanvac-B) was initiated among the Nicobarese tribe in Car Nicobar Island. The 936 individuals negative for HBsAg and anti-HBs were administered three doses of the vaccine at 0, 1 and 6 months. The vaccine was found to be safe and efficacious with sero-protection rates of 49.1, 86.9 and 96.7% after first, second and third dose. Considering the high endemicity of the infection and small number of the tribal population, it is necessary to initiate hepatitis-B vaccination programme for this community. Since the vaccine was found to be cost-effective, it could be adopted for hepatitis-B vaccination in this community.
AuthorsM V Murhekar, K M Murhekar, V A Arankalle, S C Sehgal
JournalVaccine (Vaccine) Vol. 20 Issue 29-30 Pg. 3431-5 (Oct 4 2002) ISSN: 0264-410X [Print] Netherlands
PMID12297387 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • Hepatitis B Antibodies
  • Hepatitis B Vaccines
  • Adolescent
  • Adult
  • Child
  • Child, Preschool
  • Female
  • Hepatitis B Antibodies (blood)
  • Hepatitis B Vaccines (adverse effects, immunology)
  • Humans
  • India
  • Infant
  • Infant, Newborn
  • Male
  • Vaccination

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!

Choose Username:
Verify Password: